LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Vivani Medical

Chiusa

1.01

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.99

Massimo

1.02

Metriche Chiave

By Trading Economics

Dipendenti

37

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+296.04% upside

Dividendi

By Dow Jones

Utili prossimi

16 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-8.3M

52M

Apertura precedente

1.01

Chiusura precedente

1.01

Vivani Medical Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 giu 2024, 15:28 UTC

I principali Market Mover

Vivani Medical Shares Up, FDA Cleared New Drug Application to Start Diabetes Trial

Confronto tra pari

Modifica del prezzo

Vivani Medical Previsione

Obiettivo di Prezzo

By TipRanks

296.04% in crescita

Previsioni per 12 mesi

Media 4 USD  296.04%

Alto 4 USD

Basso 4 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Vivani Medical - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

2

Acquista

0

Mantieni

0

Vendi

Notizie finanziarie

$

Chi Siamo Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.